<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PLASMA PROTEIN FRACTION</span><br/>(plas'ma)<br/><span class="topboxtradename">Plasmanate, </span><span class="topboxtradename">Plasma-Plex, </span><span class="topboxtradename">Plasmatein, </span><span class="topboxtradename">PPF, </span><span class="topboxtradename">Protenate<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">plasma volume expander</span><br/><b>Prototype: </b>Normal serum albumin, human<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>5% injection</p>
<h1><a name="action">Actions</a></h1>
<p>Oncotic action approximately equivalent to that of human plasma; does not provide coagulation factors or gamma globulins.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Heat-treated to minimize hazard of transmitting serum hepatitis; risk of sensitization is reduced because it lacks cellular
         elements. Does not require cross matching.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Emergency treatment of hypovolemic shock due to burns, trauma, surgery, infections; temporary measure in treatment of blood
         loss when whole blood is not available; to replenish plasma protein in patients with hypoproteinemia (if sodium restriction
         is not a problem).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe anemia; cardiac failure; patients undergoing cardiopulmonary bypass surgery; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Patients with low cardiac reserve; absence of albumin deficiency; liver or kidney failure.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Plasma Volume Expansion</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 250500 mL at a maximum rate of 10 mL/min<br/><span class="rdage">Child:</span> <span class="rdroute">IV</span> 6.633 mL/kg at a rate of 510 mL/min<br/><br/><span class="indicationtitle">Hypoproteinemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV</span> 11.5 L/d infused at a rate not to exceed 58 mL/min<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>Do not use solutions that show a sediment or appear turbid.</li>
<li>Do not use solutions that have been frozen.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Give undiluted. Once container is opened, solution should be used within 4 h because it contains no preservatives. Discard
                  unused portions.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> Rate of infusion and volume of total dose will depend on patient's age, diagnosis, degree of venous and pulmonary congestion,
                  Hct, and Hgb determinations. As with any oncotically active solution, infusion rate should be relatively slow. Range may vary
                  from 110 mL/min.  
               </p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">GI:</span> Nausea, vomiting, hypersalivation, headache. <span class="typehead">Body as a Whole:</span>  Tingling, chills, fever, cyanosis, chest tightness, backache, urticaria, erythema, <span class="speceff-life">shock (systemic anaphylaxis)</span>, circulatory overload, pulmonary edema. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> No clinically significant interactions established. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1>Not studied. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor vital signs (BP and pulse). Frequency depends on patient's condition. Flow rate adjustments are made according to
            clinical response and BP. Slow or stop infusion if patient suddenly becomes hypotensive.
         </li>
<li>Report a widening pulse pressure (difference between systolic and diastolic); it correlates with increase in cardiac output.</li>
<li>Report changes in I&amp;O ratio and pattern.</li>
<li>Observe patient closely during and after infusion for signs of hypervolemia or circulatory overload (see Appendix F). Report
            these symptoms immediately to physician.
         </li>
<li>Make careful observations of patient who has had either injury or surgery in order to detect bleeding points that failed to
            bleed at lower BP.
         </li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>